x-kidney diagnostics GmbH was incorporated in 2019 and is based in Erfurt, Germany. The company is dedicated to the development of new methods for the early identification of kidney diseases.

The early diagnosis of kidney diseases is essential for their successful treatment and management. However, the early dioganosis is hampered by the lack of biomarkers for early stages. Currently, clinically validated biomarkerare recognized when the kidney is already damaged by 50%. Diabetic nephropathy is the most common cause of dialysis in Europe and the United States.

x-kidney diagnostics GmbH focuses on the identification of novel biomarkers by a proteomic based research approach in the Alport syndrome, a glomerulonephropathy with well defined animal models. Based on the comparable histopathogenesis of different glomerulonephropathies, Alport syndrome was used as surrogate model.In animals (mice and dogs) with Alport syndrome over 100 differentially expressed proteins could be identified before the onset of the disease. The most promising biomarker will be validated in a dataset of approximately 200clinically well described Alport syndrome patients with serum, plasma and urine samples. After the successful validation of the biomarkers in humans, the next step is the development of diagnostic test for the early detection of kidney disease.

‍